Alexion Pharmaceuticals stocks surged 33.09% to $161.1 in the pre-market session following a report that AstraZeneca and Alexion Pharmaceuticals (ALXN) have signed a formal deal about the purchase of Alexion by AstraZeneca.
As demonstrated by American Depositary Receipts (ADRs), for each Alexion share, Alexion shareholders would earn $60 in cash and 2,1243 AstraZeneca American Depositary Shares (ADSs). This means a cumulative consideration of $39bn or $175 per share to Alexion shareholders based on AstraZeneca’s reference average ADR price of $54.14.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
The boards of both companies have overwhelmingly approved the acquisition. The merger is scheduled to close in Q3 2021, subject to receipt of regulatory clearances and shareholders’ consent in both companies. Upon closure, Alexion shareholders will control approximately 15 percent of the merged business.
To produce life-changing drugs, both businesses have the same commitment to research and engineering. Both organizations’ skills will develop a business with strong strengths through many technological channels and produce revolutionary drugs for millions of people around the world. The merged business would also provide an increased geographic presence and broad reach across the core, specialty, and highly specialized care.